Pronota and Molecuence announce col­lab­o­ra­tion in pro­tein bio­mark­er dis­cov­ery.

Ghent, Belgium, 22th February 2011 – Pronota NV today announced that it has entered into an agree­ment with Molecuence Corporation, a whol­ly owned sub­sidiary of Mitsubishi Chemical Corporation, to dis­cov­er and val­i­date pro­tein bio­mark­ers in stroke. Pronota will apply its proven pro­pri­etary plat­forms for pro­tein bio­mark­er dis­cov­ery (MASStermind®) and bio­mark­er ver­i­fi­ca­tion MASSterclass™) to this project. The finan­cial terms have not been dis­closed.

“We’re find­ing poten­tial col­lab­o­ra­tors are increas­ing­ly per­suad­ed by our track record of not only being able to iden­ti­fy nov­el pro­tein bio­mark­ers, but also of tak­ing these suc­cess­ful­ly through the ver­i­fi­ca­tion process to show they are true, robust and clin­i­cal­ly rel­e­vant dis­cov­er­ies. We’re delight­ed to be work­ing with Molecuence, who are one of the lead­ers in the field of pro­tein bio­mark­er devel­op­ment for diag­nos­tic appli­ca­tions”, com­ment­ed Nick McCooke, CEO of Pronota.

About Pronota

Pronota was found­ed in late 2004 to devel­op pro­tein bio­mark­er diag­nos­tics derived from its pro­pri­etary plat­form that unique­ly mines for low-abun­dance pro­tein bio­mark­ers in blood and oth­er tis­sues. In this short time, it has suc­cess­ful­ly imple­ment­ed its tech­nol­o­gy and made sub­stan­tial progress in cre­at­ing a diag­nos­tic prod­uct devel­op­ment pipeline.

Its MASStermind® pro­tein bio­mark­er dis­cov­ery plat­form has demon­strat­ed, across many projects, its unerr­ing abil­i­ty to dis­cov­er clin­i­cal­ly rel­e­vant and nov­el pro­tein bio­mark­ers. Its MASSterclass™ ver­i­fi­ca­tion plat­form pro­vides it with a way of ver­i­fy­ing with­in a mat­ter of weeks the pro­lif­ic out­put from MASStermind with­out hav­ing to resort to the use of anti­body based assays.

About Molecuence

Molecuence Corporation is a whol­ly owned sub­sidiary of Mitsubishi Chemical Corporation. The com­pa­ny is prin­ci­pal­ly involved in the devel­op­ment of dis­ease relat­ed bio­mark­ers that can enable diag­no­sis and pre­dic­tion of accu­rate dis­ease sta­tus. Currently, the com­pa­ny is involved in research and devel­op­ment of advanced bio­mark­ers for car­dio­vas­cu­lar and meta­bol­ic dis­eases. Molecuence works in part­ner­ship with Kyushu uni­ver­si­ty fac­ul­ty of med­i­cine and Hisayama research insti­tute for lifestyle dis­eases. The com­pa­ny is head­quar­tered in Yokohama, Japan.

Leave a Reply

Your email address will not be published. Required fields are marked *